Carcinoid syndrome MRI: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(Mahshid) |
||
Line 23: | Line 23: | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Endocrinology]] | |||
[[Category:Surgery]] |
Revision as of 02:39, 6 November 2017
Carcinoid syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Carcinoid syndrome MRI On the Web |
American Roentgen Ray Society Images of Carcinoid syndrome MRI |
Risk calculators and risk factors for Carcinoid syndrome MRI |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
On abdominal MRI, carcinoid tumor is characterized by nodular mass originating from the bowel wall or regional uniform bowel wall thickening with moderate intense enhancement on postgadolinium T1-weighted fat-suppressed images. Abdominal MRI scan may be performed to detect metastases of carcinoid syndrome to liver and mesentery.
MRI
On abdominal MRI, carcinoid syndrome is characterized by:[1]
- Nodular mass originating from the bowel wall or regional uniform bowel wall thickening with moderate intense enhancement on postgadolinium T1-weighted fat-suppressed images.
- Mesenteric metastases presented as nodular masses with mesenteric stranding.
- Liver metastases may show hypointense precontrast T1- and hyperintense T2-weighted images.
- Liver metastases are commonly hypervascular.
References
- ↑ Bader TR, Semelka RC, Chiu VC, Armao DM, Woosley JT (2001). "MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver". J Magn Reson Imaging. 14 (3): 261–9. PMID 11536403.